

**Table SI. Patients' demographics**

Variable	Biologicals	Methotrexate	
		> 24 months	< 24 months
Number, <i>n</i>	32	122	47
Female, <i>n</i> (%)	6 (18.8)	52 (41.9)*	17 (34.7)
Median age, years (range)	48 (18–76)	60 (22–82)*	50 (20–76)
Duration of psoriasis, years (range)	20 (21–38)	27 (5–66)**	24 (4–53)
Type of psoriasis, <i>n</i>			
Chronic plaque psoriasis	32	122	47
Palmoplantar pustulosis		2	1
Acrodermatitis continua	2	1	
BMI, median (range)	27 (21–38)	28 (19–42)	27 (20–40)
> 25, <i>n</i> (%)	25 (75)	82 (68)	31 (69)
> 30, <i>n</i> (%)	13 (41)	37 (31)	15 (33)
> 40, <i>n</i> (%)	0	1 (0.8)	0
Diabetes mellitus, <i>n</i> (%)	7 (21.8)	20 (16.1)	5 (10.2)
Methotrexate therapy, months, median (range)	0	60 (25–432)	16 (1–24)
Concomitant systemic therapy, <i>n</i>			
Etanercept	11	11	8
Adalimumab	11	10	9
Infliximab	5	4	0
Ustekinumab	5	2	9
Transient elastography (TE) median (range)	5.65 (3.0–12.0)	5.9 (2.3–25.7)	5.5 (3.1–36.3)
TE >6.5 kPa (>5.5 kPa XL-probe), <i>n</i> (%)	12 (37.5)	46 (37.7)	15 (31.9)
TE >11.5 kPa (>10.5 kPa XL-probe), <i>n</i> (%)	1 (3.1)	11 (9)	3 (6.4)
Procollagen III median (range)	Not done	500 (260–1,400)	460 (320–670)
Procollagen III > 800 IU/l, <i>n</i> (%)	Not done	6 (5)	0
APRI median (range)	0.26 (0.14–0.65)	0.23 (0.06–1.39)	0.24 (0.06–1.60)
FIB-4 median (range)	1.05 (0.42–4.55)	1.16 (0.28–5.69)	0.97 (0.33–4.24)
AST/ALT median (range)	0.80 (0.51–3.28)	0.96 (0.42–3.69)	0.81 (0.29–1.82)

BMI: body mass index; AST: aspartate transaminase; ALT: alanine transaminase; FIB-4: Fibrosis-4 ; APRI: AST to Platelet Ratio Index. Differences between groups \* $p < 0.05$ , \*\* $p < 0.01$ .